A drug under study to treat various cancers selectively kills cancer cells because of its affinity for a modified version of a critical heat shock protein they contain, researchers have found.
They found in cancer a modified version of heat shock protein 90, or hsp90, which like most heat shock proteins, promotes cell survival.